{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:00:03Z","timestamp":1778169603364,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"9700","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/s0140-6736(09)61416-1","type":"journal-article","created":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T05:09:48Z","timestamp":1253336988000},"page":"1512-1520","source":"Crossref","is-referenced-by-count":573,"title":["High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial"],"prefix":"10.1016","volume":"374","clinical-trial-number":[{"clinical-trial-number":"nct00210314","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andr\u00e9s JM","family":"Ferreri","sequence":"first","affiliation":[]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Foppoli","sequence":"additional","affiliation":[]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[]},{"given":"Gerasimus A","family":"Pangalis","sequence":"additional","affiliation":[]},{"given":"Maurizio","family":"Frezzato","sequence":"additional","affiliation":[]},{"given":"Maria Giuseppina","family":"Cabras","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[]},{"given":"Gaetano","family":"Corazzelli","sequence":"additional","affiliation":[]},{"given":"Fiorella","family":"Ilariucci","sequence":"additional","affiliation":[]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[]},{"given":"Riccardo","family":"Soffietti","sequence":"additional","affiliation":[]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[]},{"given":"Luc\u00eda","family":"Zoppegno","sequence":"additional","affiliation":[]},{"given":"Gian Marco","family":"Aondio","sequence":"additional","affiliation":[]},{"given":"Giuseppe","family":"Avvisati","sequence":"additional","affiliation":[]},{"given":"Monica","family":"Balzarotti","sequence":"additional","affiliation":[]},{"given":"Alba A","family":"Brandes","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Fajardo","sequence":"additional","affiliation":[]},{"given":"Henry","family":"Gomez","sequence":"additional","affiliation":[]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[]},{"given":"Graziella","family":"Pinotti","sequence":"additional","affiliation":[]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[]},{"given":"Catrina","family":"Uhlmann","sequence":"additional","affiliation":[]},{"given":"Piero","family":"Picozzi","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Vezzulli","sequence":"additional","affiliation":[]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[]},{"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(09)61416-1_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","article-title":"A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy","volume":"89","author":"Mead","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(09)61416-1_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1023\/A:1008376412784","article-title":"Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials","volume":"11","author":"Ferreri","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib3","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","article-title":"Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(09)61416-1_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","article-title":"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","volume":"43","author":"Guha-Thakurta","year":"1999","journal-title":"J Neurooncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib6","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib8","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ana.20495","article-title":"NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report","volume":"57","author":"Herrlinger","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","article-title":"Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome","volume":"81","author":"Glass","year":"1994","journal-title":"J Neurosurg"},{"key":"10.1016\/S0140-6736(09)61416-1_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2005.07.958","article-title":"Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)","volume":"64","author":"O'Brien","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S0140-6736(09)61416-1_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib13","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V86.8.2922.2922","article-title":"The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression","volume":"86","author":"Blay","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(09)61416-1_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.1996.14.3.945","article-title":"Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD\/BVAM chemotherapy before radiotherapy","volume":"14","author":"Bessell","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/10428199809057573","article-title":"Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy","volume":"30","author":"Korfel","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S0140-6736(09)61416-1_bib16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0360-3016(98)00002-9","article-title":"Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL)","volume":"40","author":"Brada","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S0140-6736(09)61416-1_bib17","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib18","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib19","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.wnl.0000210464.94122.e1","article-title":"MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas","volume":"66","author":"Ferreri","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(09)61416-1_bib21","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0360-3016(01)01639-X","article-title":"Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate","volume":"51","author":"Reni","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S0140-6736(09)61416-1_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(09)61416-1_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib25","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib28","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib29","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(09)61416-1_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3171\/jns.1999.91.2.0221","article-title":"Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas","volume":"91","author":"Hiraga","year":"1999","journal-title":"J Neurosurg"},{"key":"10.1016\/S0140-6736(09)61416-1_bib32","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma","volume":"23","author":"Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/10428190109099335","article-title":"Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma","volume":"42","author":"Harjunpaa","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S0140-6736(09)61416-1_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(09)61416-1_bib35","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1080\/10428190802381238","article-title":"High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions","volume":"49","author":"Ferreri","year":"2008","journal-title":"Leuk Lymphoma"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673609614161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673609614161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T05:50:41Z","timestamp":1590126641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673609614161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":35,"journal-issue":{"issue":"9700","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0140673609614161"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(09)61416-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1382969.2952065","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1382969.855068","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}